Revenue segments as reported by the company.

Technology & Analytics Solutions

Research & Development Solutions

Contract Sales & Medical Solutions

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Depreciation and amortization

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

IQVIA Hlds

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IQVIA reports solid Q4 performance, addresses macro challenges proactively

IQVIA delivered a strong performance in Q4 2022 with revenue growth, operational achievements, and solid financial guidance for 2023, underlining its market position and strategic focus.
While facing challenges from macroeconomic factors, wage inflation, and market conditions, the company is proactively addressing these issues through cost-cutting measures and debt reduction strategies.
By leveraging its strengths in stable operations, record bookings, and financial discipline, IQVIA aims to navigate challenges, capitalize on opportunities, and drive sustainable growth in the future.

IQVIA reports solid Q1 growth amidst industry challenges and opportunities

IQVIA Hlds (IQV) Q1 2023 reflects strong financial performance and operational resilience.
Challenges in backlog burn and industry dynamics are being managed effectively.
Opportunities in M&A activity and demand for real-world evidence drive growth.
Steady guidance for 2023 positions the company well for future success.

IQVIA posts strong Q2 results, eyes growth amid AI investments

IQVIA's Q2 performance reflects solid growth and strategic wins in data and analytics solutions.
While facing challenges in decision delays and economic uncertainties, the company's AI investments and strong R&DS segment offer growth opportunities.
With a focus on leveraging AI across business areas and a vast patient data advantage, IQVIA is well-positioned for future success.

IQVIA reports mixed Q3 results, eyes growth through strategic initiatives

IQVIA's Q3 2023 performance showcased strength in R&DS bookings and revenue growth, while TAS faced challenges from foreign exchange and weak demand. The company aims to drive growth through new contracts, cost reduction initiatives, and strategic pricing adjustments, with a focus on stabilizing performance and pursuing growth opportunities in 2024.

IQVIA reports robust Q4 earnings, eyes growth amid challenges

IQVIA's strong performance in bookings and revenue growth positions it well for future success.
While facing challenges in TAS and pricing negotiations, IQVIA's contract wins and guidance for 2024 show resilience.
Opportunities lie in improving demand for TAS, increasing RFPs, and growth in the data business.
Overall, IQVIA's strategic wins and financial outlook indicate a positive trajectory for the company.

IQVIA reports solid Q1 performance, eyes growth through partnerships

IQVIA delivered a solid performance in Q1 2024, meeting revenue expectations and showcasing growth in bookings and pipeline. The company's strengths lie in technology-enabled solutions, global partnerships, and public health initiatives.
Challenges include cancellations impacting revenue, pricing pressures, and the need to navigate market dynamics. However, IQVIA's opportunities in innovation, partnerships, and market expansion position it well for future growth.
Overall, IQVIA's strategic focus on technology, client engagements, and public health initiatives, amidst challenges in cancellations and pricing pressures, presents a resilient outlook. The company's financial performance and industry leadership are key strengths.
With a proactive approach to challenges and a focus on seizing opportunities, IQVIA remains well-positioned for sustained growth and success in the evolving healthcare landscape. The company's adaptability and strategic initiatives drive confidence in its future prospects.

IQVIA reports robust Q2 earnings, eyes growth amidst market challenges

IQVIA Hlds delivered a strong Q2 performance with revenue and earnings growth, supported by efficient operations and solid financial metrics.
While facing challenges such as pricing pressures and market dynamics, the company remains optimistic about future opportunities and growth potential.
Strategic focus on addressing challenges and seizing opportunities will be key to sustaining performance and maximizing shareholder value in the dynamic healthcare landscape.

IQVIA Hlds reports Q3 growth, faces study delays and pricing challenges

IQVIA Hlds demonstrated solid financial performance in Q3 2024, driven by revenue growth and increased EPS.
While facing challenges like study delays and pricing pressures, the company's strategic strengths and opportunities for growth remain intact.
With a focus on share buybacks and R&DS growth, IQVIA is positioning itself for sustained success in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Examine the evolution of IQVIA's (IQV) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Understanding IQVIA (IQV) Reliance on International Revenue

Investors interested in Medical - Instruments stocks are likely familiar with IQVIA Holdings (IQV) and Waters (WAT). But which of these two companies is the best option for those looking for undervalued stocks?

IQV vs. WAT: Which Stock Should Value Investors Buy Now?

IQVIA Holdings Inc IQV posted better-than-expected second-quarter earnings on Monday.

These Analysts Boost Their Forecasts On IQVIA After Better-Than-Expected Earnings

Although the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, IQVIA (IQV) Q2 Earnings: A Look at Key Metrics

IQVIA Holdings (IQV) beat second-quarter earnings expectations and raised its full-year outlook on Monday, sending shares higher.

IQVIA Stock Pops After It Beats Q2 Earnings Estimates

IQVIA Holdings Inc. (NYSE:IQV ) Q2 2024 Earnings Conference Call July 22, 2024 9:00 AM ET Company Participants Kerri Joseph - SVP, IR & Treasury Ari Bousbib - Chairman & CEO Ron Bruehlman - EVP & CFO Conference Call Participants Shlomo Rosenbaum - Stifel David Windley - Jefferies Anne Samuel - JP Morgan Elizabeth Anderson - Evercore ISI Max Smock - William Blair Jailendra Singh - Truist Securities Justin Bowers - Deutsche Bank Dan Leonard - UBS Charles Rhyee - TD Cowen Michael Ryskin - Bank of America Jack Wallace - Guggenheim Securities Patrick Donnelly - Citi Matt Sykes - Goldman Sachs Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA Second Quarter 2024 Earnings Conference Call.

IQVIA Holdings Inc. (IQV) Q2 2024 Earnings Call Transcript

IQVIA's (IQV) second-quarter 2024 earnings and revenues increase year over year.

IQVIA (IQV) Surpasses Earnings & Revenue Estimates in Q2

IQVIA Holdings Inc IQV reported a second adjusted EPS of $2.64, up from $2.43, beating the consensus of $2.57.

IQVIA 'Is A Solid Investment' With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings

Iqvia stock bolted higher Monday after the contract research firm raised its outlook for the year on the back of unexpected strength.

Iqvia Bolts Higher After A Surprise Segment Beat Saved Its Second Quarter

IQVIA Holdings (IQV) came out with quarterly earnings of $2.64 per share, beating the Zacks Consensus Estimate of $2.58 per share. This compares to earnings of $2.43 per share a year ago.

IQVIA Holdings (IQV) Q2 Earnings and Revenues Surpass Estimates

Contract research firm IQVIA Holdings raised its forecast for full-year profit on Monday, banking on strength in demand for its healthcare data and analytics services.

IQVIA raises annual profit forecast on improving demand for analytics services

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2024. Second-Quarter 2024 Operating Results Revenue for the second quarter of $3,814 million increased 2.3 percent on a reported basis and 3.5 percent at constant currency, compared to the second quarter of 2023.

IQVIA Reports Second-Quarter 2024 Results

IQVIA's (IQV) second-quarter 2024 revenues are likely to have gained from growth in the Technology and Analytics, and Research and Development segments.

IQVIA (IQV) to Report Q2 Earnings: What's in the Offing?

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV) today announces that a leading, independent research firm, Everest Group, has recognized IQVIA as a Leader in its Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment 2024 survey, which measures both market impact and delivery effectiveness. The Everest Group report highlights IQVIA's focus on innovation and its comprehensive portfolio of solutions that accelerates drug development from molecule to marke.

IQVIA Named a Leader in Medical Affairs and Regulatory Operations by Everest Group

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its second-quarter 2024 financial results before the market opens on Monday, July 22, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation sl.

IQVIA to Announce Second-Quarter 2024 Results on July 22, 2024

IQVIA (IQV) benefits from its healthcare-specific global IT infrastructure and domain expertise to expand and penetrate different markets.

Clinical Development Expertise Aids IQVIA (IQV), Costs High

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the IQVIA SmartSolve Enterprise Quality Management System (eQMS) platform has been selected as the winner of the “Best Use of Artificial Intelligence in Healthcare" award in the 8th Annual MedTech Breakthrough Awards. SmartSolve eQMS is part of IQVIA's suite of purpose-built s.

IQVIA's SmartSolve® eQMS Wins 2024 MedTech Breakthrough Award “Best Use of Artificial Intelligence in Healthcare”

IQVIA's (IQV) One Home for Sites allows pharmaceutical companies and their software vendors to streamline clinical application management.

IQVIA (IQV) Announces Launch of Trial Technology Platform

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV) today announced the launch of One Home for Sites™, a new technology platform that acts as a single sign-on and a single dashboard for the key systems and tasks a clinical research site needs to perform across all of the clinical trials it is conducting. Clinical research sites manage scores of usernames and passwords in dozens of software applications as they navigate through numerous tasks they must complete each day in conducting.

IQVIA Launches “One Home” Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--As cancer incidence continues to rise, it's being met by wider use of innovative therapies and a robust pipeline of new drugs, according to a new report from the IQVIA Institute for Human Data Science titled, “Global Oncology Trends 2024: Outlook to 2028.” “The global oncology ecosystem is operating near peak levels to address increasing challenges. New therapies for advanced cancers, including some of the most advanced novel science in the industr.

IQVIA Institute: Innovative Therapies and Strong Pipeline to Combat Rise in Cancer Diagnoses

There have been numerous positive updates to IQVIA Holdings' fundamental economics since January 2023. It produced strong Q1 2024 earnings, with growth observed in all segments. Increasing returns from margin growth and capital productivity are driving exceptional free cash flow production.

IQVIA: Long-Term Compounder Throwing Off Free Cash Flow

IQVIA (IQV) benefits from a powerful healthcare-specific global IT infrastructure and a robust real-world solutions ecosystem. However, high operating expenses are a headwind.

Here's Why You Should Hold on to IQVIA (IQV) Stock for Now

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Overall spending in the U.S. market for medicines grew by 2.5% and reached $435Bn in 2023. Excluding the contribution from COVID-19 vaccines and therapeutics, spending grew at 9.9%, according to a new report from the IQVIATM Institute for Human Data Science, The Use of Medicines in the U.S. 2024: Usage and Spending Trends and Outlook to 2028. The drop in COVID-19 vaccines and therapeutics masks the significant growth in medicines that are bringing.

U.S. Medicines Spending Grew in 2023 as Greater Access Offset COVID-19-related Decline, Says IQVIA Institute

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Bank of America Health Care Conference in Las Vegas on Tuesday, May 14, 2024 at 12:20 p.m. ET (9:20 a.m. local PT). A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About.

IQVIA CFO Ron Bruehlman to Speak at the Bank of America Health Care Conference on May 14, 2024

IQVIA's (IQV) rise in segmental revenues results in y/y top-line growth in first-quarter 2024.

News for IQVIA Hlds Stock (IQV)